ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three ...

Viruses are microscopic pathogens composed of genetic material housed within a protective protein shell. While they carry the ...

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and ...

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 ...

Fast Track designation highlights potential of INX-315 to address unmet need for patients with recurrent advanced/metastatic cancer RESEARCH TRIANGLE PARK, N.C., April 29, 2025 (GLOBE NEWSWIRE ...

Immunohistochemical staining (Panels C through F) shows that the lymphoid ... The absence of immunophenotypic aberrancy on plasma cells, cyclin D1 expression, bone marrow involvement, and other ...

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC. Topline data from DENALI Part 2 anticipated by year end 2026 with the potenti ...

Here, the authors show that phosphorylation of Cdk1 substrates is influenced by a phosphate-binding pocket on the surface of the cyclin regulatory subunit. Filamin C is a key actin-binding protein ...

In a 286-patient Phase 2 trial, elraglusib combined with gemcitabine/nab-paclitaxel achieved a statistically significant ...

This safety review evaluated the risk of rhabdomyolysis due to a drug interaction between cyclin-dependent kinase inhibitors (CDKIs ... A Notice of Compliance with Conditions (NOC/c) is a form of ...